89bio Inc (ETNB)
8.01
-0.74
(-8.46%)
USD |
NASDAQ |
Nov 15, 12:31
89bio Free Cash Flow (Quarterly): -145.36M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -145.36M |
| June 30, 2024 | -61.16M |
| March 31, 2024 | -39.72M |
| December 31, 2023 | -34.29M |
| September 30, 2023 | -30.36M |
| June 30, 2023 | -34.45M |
| March 31, 2023 | -30.08M |
| December 31, 2022 | -27.10M |
| September 30, 2022 | -14.82M |
| June 30, 2022 | -14.83M |
| March 31, 2022 | -24.35M |
| December 31, 2021 | -28.27M |
| Date | Value |
|---|---|
| September 30, 2021 | -13.47M |
| June 30, 2021 | -20.12M |
| March 31, 2021 | -14.99M |
| December 31, 2020 | -14.03M |
| September 30, 2020 | -12.96M |
| June 30, 2020 | -11.57M |
| March 31, 2020 | -7.813M |
| December 31, 2019 | -11.24M |
| September 30, 2019 | -6.205M |
| June 30, 2019 | -3.982M |
| March 31, 2019 | -4.169M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-145.36M
Minimum
Sep 2024
-7.813M
Maximum
Mar 2020
-29.55M
Average
-22.24M
Median
Free Cash Flow (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | -67.76M |
| Eli Lilly and Co | -458.90M |
| Viking Therapeutics Inc | -21.96M |
| Akero Therapeutics Inc | -70.42M |
| NovaBay Pharmaceuticals Inc | -2.063M |